Skip to main content

Advertisement

SpringerLink
Log in

Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Glucocorticoids (GC) are widely used to treat systemic sclerosis (SSc). The lack of efficacy data and patient/physician concerns may prompt therapy discontinuation. The aim of this study is to identify factors hampering GC discontinuation in patients with stable disease on oral GC for longer than 12 months. Consecutive patients fulfilling the 2013 ACR/EULAR criteria for SSc and with stable disease were prescribed a slow tapering GC regimen to achieve discontinuation. At study entry and 6 months later (T6), patients were assessed for disease activity and severity. Moreover, the Short-Form-36; the Health Assessment Questionnaire Disability Index (HAQ-DI); and visual analog scales for fatigue, pain, and general health were completed. Reasons for stopping the discontinuation regimen were recorded. Forty-eight patients (46 females, 9 diffuse SSc), with a mean ± SD age of 56±14 years and a median disease duration of 10 years (range 2–22), were enrolled. The median daily GC dose was 5 mg (range 5–10; all patients treated with prednisone). At T6, 33 (68.7 %) patients had discontinued GC. The remaining 15 patients could not discontinue GC because of arthralgia in eight, arthritis in two, puffy fingers in two, increased creatine-kinase in two, and bursitis in one patient. At multiple logistic analysis, a higher baseline HAQ-DI was the only independent factor associated with GC need (OR 2.98, 95 % CI 1.20–7.41; p = 0.01). About one third of SSc patients did not achieve a GC-free regimen. Disability as assessed by HAQ-DI was the leading factor hindering GC discontinuation. A low HAQ-DI score can identify candidates for GC discontinuation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 60:1989–2003

    Article  Google Scholar 

  2. Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 10:344–6

    Article  Google Scholar 

  3. Jacobs JW, Bijlsma JW (2011) Glucocorticoids in rheumatology: indications and routes of administration. Clin Exp Rheumatol 29(5 Suppl 68):S81–4

    CAS  PubMed  Google Scholar 

  4. Posnik J (1963) Systemic lupus erythematosus. The effect of corticotropin and adrenocorticoid therapy on survival rate. Calif Med 98:308–12

    Google Scholar 

  5. Albert DA, Hadler NM, Ropes MW (1979) Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum 22:945–53

    Article  CAS  PubMed  Google Scholar 

  6. Iudici M, Fasano S, Iacono D et al (2014) Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol 33:153–64

    Article  PubMed  Google Scholar 

  7. Hunzelmann N, Moinzadeh P, Genth E et al (2009) High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 11:R30

    Article  PubMed  PubMed Central  Google Scholar 

  8. Iudici M, van der Goes MC, Valentini G, Bijlsma JW (2013) Glucocorticoids in systemic sclerosis: weighing the benefits and risks—a systematic review. Clin Exp Rheumatol 31(2 Suppl 76):157–65

    PubMed  Google Scholar 

  9. Postolova A, Chen JK, Chung L (2016) Corticosteroids in myositis and scleroderma. Rheum Dis Clin North Am 42:103–18

    Article  PubMed  Google Scholar 

  10. Steen VD (2003) Scleroderma renal crisis. Rheum Dis Clin North Am 29:315–33

    Article  PubMed  Google Scholar 

  11. Iudici M, Russo B, Mitidieri M, Cuomo G, Valentini G (2015) Glucocorticoids in systemic sclerosis: patients’ beliefs and treatment adherence. Scand J Rheumatol 44:229–37

    Article  CAS  PubMed  Google Scholar 

  12. Arena C, Morin AS, Blanchon T et al (2010) Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol 163:832–7

    Article  CAS  PubMed  Google Scholar 

  13. Fardet L, Flahault A, Kettaneh A et al (2007) Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol 157:142–8

    Article  CAS  PubMed  Google Scholar 

  14. van der Goes MC, Jacobs JWJ, Boers M et al (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 69:1913–19

    Article  PubMed  Google Scholar 

  15. Mosca M, Tani C, Aringer M (2013) Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? Clin Exp Rheumatol 31:S71–4

    PubMed  Google Scholar 

  16. Luqmani RA (2013) Discontinuation of therapies in vasculitis. Clin Exp Rheumatol 31:S93–7

    PubMed  Google Scholar 

  17. Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD (2005) Prolonged remission in systemic lupus erythematosus. J Rheumatol 32:1467–72

    PubMed  Google Scholar 

  18. van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 72:1747–55

    Article  PubMed  Google Scholar 

  19. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21:S42–6

    PubMed  Google Scholar 

  20. Valentini G, Cuomo G, Abignano G et al (2011) Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 50:317–2

    Article  Google Scholar 

  21. Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Walker UA, Tyndall A, Czirjak L et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 66:754–63

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–5

    CAS  PubMed  Google Scholar 

  24. Valentini G, Marcoccia A, Cuomo G et al (2013) Early systemic sclerosis: marker antibodies and video capillaroscopic findings are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 15:R63

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Apolone G, Mosconi P (1998) The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 51:1025–36

    Article  CAS  PubMed  Google Scholar 

  26. La Montagna G, Cuomo G, Chiarolanza I, Ruocco L, Valentini G (2006) [HAQ-DI Italian version in systemic sclerosis]. Reumatismo 58:112–5

    PubMed  Google Scholar 

  27. Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM (2015) Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100:2171–80

    Article  CAS  PubMed  Google Scholar 

  28. Alves C, Robazzi T, Mendonca M (2008) Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J) 84:192–202

    Article  Google Scholar 

  29. Amatruda TT, Hollingsworth D, D’Esopo ND et al (1960) A study of the mechanism of the steroid withdrawal syndrome. Evidence for integrity of the hypothalamic-pituitary-adrenal system. J Clin Endocrinol Metab 20:339–54

    Article  CAS  PubMed  Google Scholar 

  30. Corzillius M, Bae S (1999) Methodological issues of corticosteroid use in SLE trials. Lupus 8:692–7

    Article  CAS  PubMed  Google Scholar 

  31. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus (2004) Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus. Arthritis Rheum 11:3427–3431

    Article  Google Scholar 

  32. AbouZaha A, Fang H, Madger LS, Petri M (2013) Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus 22:697–701

    Article  Google Scholar 

  33. Tseng CE, Buyon J, Kim M et al (2006) The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus. Arthritis Rheumatol 54:3623–32

    Article  CAS  Google Scholar 

  34. Luqmani R (2013) Discontinuation of therapies in vasculitis. Clin Exp Rheumatol 31(Suppl. 78):S93-S97

  35. Spiera RF, Mitnick HJ, Kupersmith M et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19:495–501

    CAS  PubMed  Google Scholar 

  36. Visvanathan S, Rahman MU, Hoffman GS et al (2011) Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis—a prospective longitudinal study. Rheumatology (Oxford) 50:2061–70

    Article  CAS  Google Scholar 

  37. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Baňares A, Fernandez-Gutierrez B (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106–14

  38. Caporali R, Scirè CA, Todoerti M, Montecucco C (2013) The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol 31(4 Suppl 78):S9–13

    PubMed  Google Scholar 

  39. Bijlsma JW (2012) Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology (Oxford);51 Suppl 4:iv9-13

  40. Pincus T, Swearingen CJ, Luta G, Sokka T (2009) Efficacy of prednisone 1–4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 68:1715–20

    Article  CAS  PubMed  Google Scholar 

  41. Cuomo G, Zappia M, Abignano G, Iudici M, Rotondo A, Valentini G (2009) Ultrasonographic features of the hand and wrist in systemic sclerosis. Rheumatology 48:1414–7

    Article  PubMed  Google Scholar 

  42. Elhai M, Guerini H, Bazeli R, et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care & Research;8:1244–1249

  43. Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y (2012) Articular involvement in systemic sclerosis. Rheumatology (Oxford) 51:1347–56

    Article  Google Scholar 

  44. Steen VD, Medsger TA Jr (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40:1984–91

    Article  CAS  PubMed  Google Scholar 

  45. Clements PJ, Kee Wong W, Hurwitz EL et al (2001) The Disability Index of the Health Assessment questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 44:653–61

    Article  CAS  PubMed  Google Scholar 

  46. Lawrence E, Pope J, Al Zahraly Z, Lalani S, Baron M (2009) The relationship between changes in self-reported disability (measured by the Health Assessment Questionnaire-HAQ) in scleroderma and improvement of disease status in clinical practice. Clin Exp Rheumato 27(54):32–7

    CAS  Google Scholar 

  47. Dinsen S, Baslund B, Klose M et al (2013) Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med 24:714–20

    Article  CAS  PubMed  Google Scholar 

  48. Kowal-Bielecka O, Landewe R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620–8

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Jean Ann Gilder (Scientific Communication SRL) for editing the text.

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, Rheumatology Section, Second University of Naples, II Policlinico, Via Pansini 5, 80131, Naples, Italy

    Michele Iudici, Serena Vettori, Barbara Russo, Veronica Giacco, Domenico Capocotta & Gabriele Valentini

Authors
  1. Michele Iudici
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serena Vettori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Veronica Giacco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Domenico Capocotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabriele Valentini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriele Valentini.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iudici, M., Vettori, S., Russo, B. et al. Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis. Clin Rheumatol 35, 1985–1991 (2016). https://doi.org/10.1007/s10067-016-3300-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-016-3300-3

Keywords

Search

Navigation